ArticleFrontiers in endocrinology2026
Glucagon-stimulated copeptin response in children: a proof-of-concept study.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The diagnostic workup of polyuria-polydipsia syndrome (PPS) is not well-established in children and adolescents, and several non-osmotic copeptin-stimulating agents have been investigated. Glucagon stimulation test (GST) induced a robust copeptin response in adults, but data in children are lacking. This study aimed to investigate copeptin response to GST in children tested for suspected growth hormone (GH) deficiency. Methods: Twenty children (9 girls, age 10.3 ± 2.9 years) with no PPS underwent GST (30 µg/kg of glucagon i.m.). Plasma glucose, GH, cortisol, and copeptin were measured before and 60, 90, 120, 150, and 180 min after glucagon injection. Results: Median copeptin concentration was 4.1 pmol/L (IQR 3.3-6.7) at baseline and 10.6 pmol/L (5.4-17.9) at peak concentration (+87% at 150 min). No adverse events were recorded. Conclusion: GST is safe and effective at enhancing copeptin secretion in children with intact neurohypophysial function, and further studies are warranted to assess its accuracy in the differential diagnosis of PPS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.